

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/591,137
Filing Date	August 30, 2006
First Named Inventor	Andrew Douglas Baxter
Art Unit	1751
Examiner Name	Not yet assigned
Attorney Docket Number	GJE-7705

Sheet

1

of

2

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-3,542,870 A	11-24-1970	Fourneau <i>et al.</i>	All
	U2	US-5,264,459 A	11-23-1993	Chelmicka-Schorr <i>et al.</i>	All
	U3	US-2005/049256 A1	03-03-2005	Lorton <i>et al.</i>	All
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 95/001096 A	01-12-1995	Howard K. Shapiro	All	
	F2	WO 97/014415 A	04-24-1997	F.H. Faulding & Co. Ltd.	All	
	F3	WO 98/011923 A	03-26-1998	Baylor College of Medicine	All	
	F4	WO 99/044610 A	09-10-1999	Merck Sharp & Dohme Ltd.	All	
	F5	WO 99/044640 A	09-10-1999	Merck Sharp & Dohme Ltd.	All	
	F6	WO 01/095902 A	12-20-2001	Respiratorius AB	All	
	F7	WO 02/036113 A	05-10-2002	Respiratorius AB	All	
	F8	WO 02/036114 A	05-10-2002	Respiratorius AB	All	
	F9	WO 02/078670 A	10-10-2002	Neuron Therapeutics, Inc.	All	
	F10	WO 03/092617 A	11-13-2003	Combinatorx, Inc.	All	
	F11	WO 03/092689 A	11-13-2003	Arakis Ltd.	All	
	F12	WO 03/097073 A	11-27-2003	Astion Development	All	
	F13	WO 2004/091540 A	10-28-2004	Theraquest Biosciences LLC	All	
	F14	WO 2005/014044 A	02-17-2005	Boehringer Ingelheim International GmbH	All	
	F15	WO 2005/034871 A	04-21-2005	Inverseon, Inc.	All	
	F16	WO 2005/041964 A	05-12-2005	Arakis Ltd.	All	
	F17					

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete if Known**

Application Number	10/591,137
Filing Date	August 30, 2006
First Named Inventor	Andrew Douglas Baxter
Art Unit	1751
Examiner Name	Not yet assigned
Attorney Docket Number	GJE-7705

Sheet 2 of 2

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	CHIZH, B. A. <i>et al.</i> , "Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil," <i>Neuropharmacology</i> , 2001, pages 212-220, Vol. 40.	
	R2	DEY, R. <i>et al.</i> , "Labetalol for Prophylactic Treatment of Intractable Migraine During Pregnancy," <i>Headache</i> , 2002, pages 642-645, Vol. 42.	
	R3	HOLEN, E. <i>et al.</i> , "Effects of $\beta_2$ adrenoceptor agonists on T-cell subpopulations," <i>APMIS</i> , 1998, pages 849-857, Vol. 106.	
	R4	KAMEI, T. <i>et al.</i> , "Comparison Between Fenoterol and Fenoterol Plus Oxitropium Bromide Delivered by Metered-Dose Inhaler with InspirEase to Relieve Acute Asthma Attack," <i>Journal of Asthma</i> , 1999, pages 67-75, Vol. 36, No. 1.	
	R5	TACHIBANA, A. <i>et al.</i> , "Inhibition by fenoterol of human eosinophil functions including $\beta_2$ -adrenoceptor-independent actions," <i>Clin. Exp. Immunol.</i> , 2002, pages 415-423, Vol. 130.	
	R6		
	R7		
	R8		
	R9		
	R10		

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	06/18/2008
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./